Skip to main content

Table 4 Cumulative incidences and relative hazards for individual and composite endpoints at 24 months

From: Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials

 

Events, no. (cumulative incidence per 100 patients at risk)

Hazard ratio (95% CI)

SCC-BMS

UC-BMS

Unadjusted

Adjusteda

P-valuea

Individual endpoints

Target-vessel revascularization

 Any

79 (10.5)

63 (8.4)

1.27 (0.91–1.77)

1.49 (1.05–2.10)

0.025

 Related to MI

20 (2.7)

10 (1.3)

2.01 (0.94–4.29)

2.46 (1.13–5.38)

0.024

 Not related to MI

63 (8.4)

57 (7.6)

1.11 (0.78–1.59)

1.31 (0.90–1.90)

0.17

Death

 All-cause

24 (3.4)

32 (4.3)

0.76 (0.45–1.28)

0.77 (0.45–1.33)

0.34

 Cardiac cause

12 (1.6)

21 (2.8)

0.57 (0.28–1.16)

0.62 (0.30–1.27)

0.19

Myocardial infarction

 Non-fatal

24 (3.2)

19 (2.6)

1.26 (0.69–2.31)

1.56 (0.83–2.91)

0.17

Stent thrombosis

 Definite

5 (0.7)

6 (0.8)

0.83 (0.25–2.71)

1.33 (0.39–4.60)

0.65

 Definite/probable

6 (0.8)

8 (1.1)

0.74 (0.26–2.15)

1.17 (0.39–3.50)

0.79

Composite endpoints

 Cardiac death, non-fatal MI, or TVR not related to MI

95 (12.5)

96 (12.6)

1.00 (0.75–1.33)

1.17 (0.87–1.57)

0.31

 Cardiac death, non-fatal MI, or definite/probable ST

36 (4.8)

36 (4.7)

1.00 (0.63–1.58)

1.15 (0.71–1.85)

0.57

  1. CI confidence interval, MI myocardial infarction, SCC-BMS silicon carbide-coated bare-metal stent, ST stent thrombosis, UC-BMS uncoated cobalt chromium bare-metal stent
  2. aAdjusted for baseline and procedural characteristics using inverse probability weighting